A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial
早期胰腺癌患者对厄洛替尼反应的基因定义特征:CONKO-005试验结果
期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2021.103327
Hoyer, K; Hablesreiter, R; Inoue, Y; Yoshida, K; Briest, F; Christen, F; Kakiuchi, N; Yoshizato, T; Shiozawa, Y; Shiraishi, Y; Striefler, J K; Bischoff, S; Lohneis, P; Putter, H; Blau, O; Keilholz, U; Bullinger, L; Pelzer, U; Hummel, M; Riess, H; Ogawa, S; Sinn, M; Damm, F